trending Market Intelligence /marketintelligence/en/news-insights/trending/M3vf3qj997oNNOBmXLdafA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Report: Gilead, GlaxoSmithKline mulling bids for United Therapeutics

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Report: Gilead, GlaxoSmithKline mulling bids for United Therapeutics

Gilead Sciences Inc. and GlaxoSmithKline plc are among suitors weighing bids for United Therapeutics Corp., the Evening Standard reported Aug. 4, citing anonymous sources.

The news outlet reported that Gilead is most likely to win a bid, while Novartis AG is another possible contender. According to the anonymous sources, United could be worth as much as $200 per share in a sale, making the purchase price around $8.7 billion.

GSK is being advised by Lazard and Citi in the process, the Evening Standard reported.